RevitalVision vision-training software
Digital Health News

Groundbreaking Study by Dr. Agarwal’s Eye Hospital on post-crosslinking surgery patients Wins ‘Best Scientific Poster Award’ at ASCRS 2024 Annual Meeting

Dr Agarwal’s Eye Hospital recently announced that their accomplished research team have been honoured with the prestigious ‘Best Scientific Poster Award’ at the 2024 Annual Meeting of the American Society for Cataract and Refractive Surgery (ASCRS). This recognition comes in light of their groundbreaking study on ‘The efficacy of RevitalVision vision-training software in improving best-corrected […]

Nanodropper Adaptor with a close-up of an eye and eyedrop bottle
Drug Updates

Landmark Non-inferiority Clinical Trial Demonstrates Nanodropper’s Positive Impact on Glaucoma Treatment

Nanodropper, Inc., an ophthalmic device company that created the eyedrop volume-reducing Nanodropper® Adaptor, announced today that its clinical trial “An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper” was published in the journal Ophthalmology. This was a prospective, multicenter, randomized, parallel-group, single-masked, active-controlled, non-inferiority trial. The trial enrolled glaucoma patients and demonstrated […]

Digital Health News

PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration following Dose Level 1 Safety Data

PharmAbcine, Inc. (“PharmAbcine” or the “Company”) (KOSDAQ: 208340), a clinical-stage public company focused on developing novel antibody therapies for patients, today announced that the Safety Review Committee (SRC) has approved advancing to dose level 2 of the PMC-403 Phase 1 clinical study in neovascular age-related macular degeneration patients following completion of dose level 1 safety data evaluation. […]

Drug Updates

First patient treated in the second dose group in Annexin’s RVO study

Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company’s clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No limiting treatment-related side effects have been reported and the company has received recommendation to proceed […]

Drug Updates

GUERISON to Set-Up its Footprints in India’s Ophthalmology Market

GUERISON, a global pharmaceutical having a surgical business concept incepted in Dubai, is setting its footprints in India’s Ophthalmology market with the highest ethics, top development, and uttermost safety standards!! Here, the values are extraordinary, and the planning is exceptional. GUERISON India, is dedicated to achieving medical surprises that improve people’s lives and accelerate technological […]